Related Experiment Video

Updated: May 6, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

959

Cardiac Hormones Target the Ras-MEK 1/2-ERK 1/2 Kinase Cancer Signaling Pathways

David L Vesely1

  • 1Departments of Internal Medicine, Molecular Pharmacology and Physiology, Cardiac Hormone Center, University of South Florida Health Sciences Center, J. A. Haley Veterans Medical Center-151, 13000 Bruce B. Downs Blvd., Tampa, Florida 33612, USA. david.vesely@va.gov.

Cancers
|November 12, 2013
PubMed

Insights

Cardiac hormones from the heart significantly reduce various cancer cells in vitro and in vivo. These hormones selectively inhibit cancer cell growth pathways without affecting healthy cells.

Area of Science:

  • Cardiovascular Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • The heart functions as an endocrine gland, producing atrial natriuretic peptide prohormone.
  • This prohormone yields four key peptide hormones with potential anticancer properties.

Purpose of the Study:

  • To investigate the anticancer effects of four cardiac-derived peptide hormones.
  • To elucidate the molecular mechanisms underlying their anti-cancer activity.

Main Methods:

  • In vitro studies on human cancer cell lines (pancreatic, breast, colon, prostate, kidney, ovarian, lung).
  • In vivo studies using human tumor xenografts in athymic mice.
  • Analysis of intracellular signaling pathways, including Ras, MEK 1/2, and ERK 1/2, mediated by cyclic GMP.
  • Immunocytochemical studies to determine intracellular localization.

Main Results:

  • Significant reduction (up to 97%) in cancer cell viability in vitro.
  • Substantial tumor elimination in vivo (up to 80% pancreatic, 66% breast, 86% small-cell lung cancer).
  • Inhibition of key cancer signaling pathways: Ras (up to 95%), MEK 1/2 phosphorylation (98%), ERK 1/2 activation (97%).
  • Complete blockade of mitogen-stimulated ERK and Ras activity in cancer cells, with no effect on healthy cells.

Conclusions:

  • Cardiac peptide hormones exhibit potent and selective anticancer activity.
  • These hormones target critical cancer cell proliferation pathways via cyclic GMP signaling.
  • Nuclear translocation of these hormones suggests a direct role in inhibiting cancer DNA synthesis.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K
Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.3K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K